1
|
Acker BA, Badescu VO, Berkenpas MB, Groppi VE, Hajós M, Higdon NR, Hurst RS, Jon Jacobsen E, Margolis BJ, McWhorter WW, Myers JK, Piotrowski DW, Rogers BN, Sarapa D, Vetman TN, Walker DP, Wall TM, Wilhite DM, Wishka DG, Xu W, Yates KM. Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596. Bioorg Med Chem Lett 2023; 93:129433. [PMID: 37557923 DOI: 10.1016/j.bmcl.2023.129433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 06/17/2023] [Accepted: 08/03/2023] [Indexed: 08/11/2023]
Abstract
The α7 nicotinic acetylcholine receptor is a calcium permeable, ligand-gated ion channel that modulates synaptic transmission in the hippocampus, thalamus, and cerebral cortex. Previously disclosed work described PNU-120596 that acts as a powerful positive allosteric modulator of the α7 nicotinic acetylcholine receptor. The initial structure-activity relationships around PNU-120596 were gleaned from screening a large thiazole library. Independent systematic examination of the aryl and heteroaryl groups resulted in compounds with enhanced potency and improved physico-chemical properties culminating in the identification of 16 (PHA-758454). In the presence of acetylcholine, 16 enhanced evoked currents in rat hippocampal neurons. In a rat model of impaired sensory gating, treatment with 16 led to a reversal of the gating deficit in a dose-dependent manner. These results demonstrate that aryl heteroaryl ureas, like compound 16, may be useful tools for continued exploration of the unique biology of the α7 nicotinic acetylcholine receptor.
Collapse
Affiliation(s)
- Brad A Acker
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | | | | | - Mihaly Hajós
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Nicole R Higdon
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Raymond S Hurst
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - E Jon Jacobsen
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | | | - Jason K Myers
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | - Bruce N Rogers
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Dusan Sarapa
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | | | - Daniel P Walker
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Theron M Wall
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - David M Wilhite
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Donn G Wishka
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Wenjian Xu
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| | - Karen M Yates
- Pfizer Worldwide Research & Development, Groton, CT 06340, USA
| |
Collapse
|
2
|
Tollefson MB, Acker BA, Jacobsen E, Hughes RO, Walker JK, Fox DN, Palmer MJ, Freeman SK, Yu Y, Bond BR. 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. Bioorg Med Chem Lett 2010; 20:3120-4. [DOI: 10.1016/j.bmcl.2010.03.111] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Tollefson MB, Acker BA, Jacobsen E, Hughes RO, Walker JK, Fox DN, Palmer MJ, Freeman SK, Yu Y, Bond BR. 1-(2-(2,2,2-Trifluoroethoxy)ethyl-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. Bioorg Med Chem Lett 2010; 20:3125-8. [DOI: 10.1016/j.bmcl.2010.03.106] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2010] [Revised: 03/25/2010] [Accepted: 03/26/2010] [Indexed: 11/30/2022]
|
4
|
Hughes RO, Rogier DJ, Jacobsen EJ, Walker JK, MacInnes A, Bond BR, Zhang LL, Yu Y, Zheng Y, Rumsey JM, Walgren JL, Curtiss SW, Fobian YM, Heasley SE, Cubbage JW, Moon JB, Brown DL, Acker BA, Maddux TM, Tollefson MB, Mischke BV, Owen DR, Freskos JN, Molyneaux JM, Benson AG, Blevis-Bal RM. Design, Synthesis, and Biological Evaluation of 3-[4-(2-Hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a Potent, Orally Active, Brain Penetrant Inhibitor of Phosphodiesterase 5 (PDE5). J Med Chem 2010; 53:2656-60. [PMID: 20196613 DOI: 10.1021/jm901781q] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Robert O. Hughes
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - D. Joseph Rogier
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - E. Jon Jacobsen
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - John K. Walker
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Alan MacInnes
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Brian R. Bond
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Lena L. Zhang
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Ying Yu
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Yi Zheng
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Jeanne M. Rumsey
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Jennie L. Walgren
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Sandra W. Curtiss
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Yvette M. Fobian
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Steven E. Heasley
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Jerry W. Cubbage
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Joseph B. Moon
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - David L. Brown
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Brad A. Acker
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Todd M. Maddux
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Mike B. Tollefson
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Brent V. Mischke
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Dafydd R. Owen
- Pfizer Global Research and Development, Ramsgate Road, Sandwich CT139NJ, U.K
| | - John N. Freskos
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - John M. Molyneaux
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Alan G. Benson
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| | - Rhadika M. Blevis-Bal
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, Missouri 63017
| |
Collapse
|
5
|
Hughes RO, Walker JK, Cubbage JW, Fobian YM, Rogier DJ, Heasley SE, Blevis-Bal RM, Benson AG, Owen DR, Jacobsen EJ, Freskos JN, Molyneaux JM, Brown DL, Stallings WC, Acker BA, Maddux TM, Tollefson MB, Williams JM, Moon JB, Mischke BV, Rumsey JM, Zheng Y, Macinnes A, Bond BR, Yu Y. Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring system. Bioorg Med Chem Lett 2009; 19:4092-6. [PMID: 19539468 DOI: 10.1016/j.bmcl.2009.06.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2009] [Revised: 05/28/2009] [Accepted: 06/01/2009] [Indexed: 11/17/2022]
Abstract
Efforts to improve the potency and physical properties of the aminopyridiopyrazinone class of PDE5 inhibitors through modification of the core ring system are described. Five new ring systems are evaluated and features that impart improved potency and improved solubility are delineated.
Collapse
Affiliation(s)
- Robert O Hughes
- Pfizer Global Research and Development, Chesterfield Parkway West, St. Louis, MO 63017, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Walker DP, Acker BA, Jon Jacobsen E, Wishka DG. Preparation of novel azabicyclic amines and α7 nicotinic acetylcholine receptor activity of derived aryl amides. J Heterocycl Chem 2009. [DOI: 10.1002/jhet.5570450131] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Daniel P. Walker
- Pfizer Global Research and Development, Pfizer, Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017
| | - Brad A. Acker
- Pfizer Global Research and Development, Pfizer, Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017
| | - E. Jon Jacobsen
- Pfizer Global Research and Development, Pfizer, Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017
| | - Donn G. Wishka
- Pfizer Global Research and Development, Pfizer, Inc., 700 Chesterfield Parkway West, Chesterfield, MO 63017
| |
Collapse
|
7
|
Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Krause M, Li KS, Hoffmann WE, Hajos M, Hurst RS, Walker DP. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett 2008; 18:3611-5. [PMID: 18490160 DOI: 10.1016/j.bmcl.2008.04.070] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Revised: 04/25/2008] [Accepted: 04/28/2008] [Indexed: 11/17/2022]
Abstract
A novel alpha7 nAChR agonist, N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (3a, PHA-709829), has been identified for the potential treatment of cognitive deficits in schizophrenia. The compound shows potent and selective alpha7 in vitro activity, excellent brain penetration, good rat oral bioavailability and robust in vivo efficacy in a rat auditory sensory gating model.
Collapse
Affiliation(s)
- Brad A Acker
- Neuroscience Research, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Walker DP, Wishka DG, Piotrowski DW, Jia S, Reitz SC, Yates KM, Myers JK, Vetman TN, Margolis BJ, Jacobsen EJ, Acker BA, Groppi VE, Wolfe ML, Thornburgh BA, Tinholt PM, Cortes-Burgos LA, Walters RR, Hester MR, Seest EP, Dolak LA, Han F, Olson BA, Fitzgerald L, Staton BA, Raub TJ, Hajos M, Hoffmann WE, Li KS, Higdon NR, Wall TM, Hurst RS, Wong EHF, Rogers BN. Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists. Bioorg Med Chem 2006; 14:8219-48. [PMID: 17011782 DOI: 10.1016/j.bmc.2006.09.019] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2006] [Revised: 09/11/2006] [Accepted: 09/11/2006] [Indexed: 11/28/2022]
Abstract
A novel set of azabicyclic aryl amides have been identified as potent and selective agonists of the alpha7 nAChR. A two-pronged approach was taken to improve the potential hERG liability of previously disclosed alpha7 nAChR agonist, PNU-282,987, while maintaining the compound's other desirable pharmacological properties. The first approach involved further exploration of the aryl carboxylic acid fragment of PNU-282,987, while the second approach focused on modification of the azabicyclic amine portion of PNU-282,987. The best compounds from each series are characterized by rapid brain penetration, good oral bioavailability in rat, and demonstrate in vivo efficacy in a rat P50 auditory sensory gating assay. At least one analog from each series (1h, 1o, 2a, 9a, and 18a) shows an improved hERG safety profile over PNU-282,987.
Collapse
Affiliation(s)
- Daniel P Walker
- Neuroscience Research, Pfizer Global Research and Development, Eastern Point Rd., Groton, CT 06340, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Affiliation(s)
- Leiming Li
- Departments of Materials Science and Engineering and Chemistry, Medical School, Northwestern University, Evanston, Illinois 60208
| | - Eugene R. Zubarev
- Departments of Materials Science and Engineering and Chemistry, Medical School, Northwestern University, Evanston, Illinois 60208
| | - Brad A. Acker
- Departments of Materials Science and Engineering and Chemistry, Medical School, Northwestern University, Evanston, Illinois 60208
| | - Samuel I. Stupp
- Departments of Materials Science and Engineering and Chemistry, Medical School, Northwestern University, Evanston, Illinois 60208
| |
Collapse
|